Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THIO-ATPA is a synthetic small molecule and a sulfur-containing analog of ATP, specifically designed as a potent and selective agonist for kainate-type ionotropic glutamate receptors, particularly the GluR5 (now known as GluK1) subunit. It is used primarily in neuropharmacological research to study excitatory neurotransmission and receptor kinetics. The compound acts by binding to the ligand-binding domain of kainate receptors, inducing channel opening and promoting calcium influx into neurons, which is critical for synaptic plasticity and signal transduction. Structural studies have shown that (S)-thio-ATPA interacts with the GluR2/GluK1 receptor core, providing insights into agonist-specific activation mechanisms[6][8]. Its high potency makes it valuable for dissecting glutamatergic signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thio-atpa.